Skip to main content

Jason Elinoff, MD

Search for Additional Doctors

Department

Select the department from the list

Specialties

Select the Doctor's Specialty

Return to Search
jelinoff.jpg

Jason Elinoff, MD

Tenure-Track Investigator
Head, Pulmonary Vascular Biology Section;
Co-Director, Translational Pulmonary Arterial Hypertension Program;
Assistant Director, 4D Lab

Tenure Track Investigator; Head, Pulm Vasc Biol Sect; Co-Director, PAH Program, Critical Care Medicine
elinoffj@mail.nih.gov
301-496-9320

Dr. Jason Elinoff is currently a Tenure-Track Investigator in the NIH Clinical Center's Critical Care Medicine Department and serves as the Co-Director of the CCMD Translational Pulmonary Arterial Hypertension Program.

AB, Princeton University
MD, University of Chicago Pritzker School of Medicine

PAH is characterized by dysregulated cell proliferation and infiltration of activated inflammatory cells leading to progressive narrowing and obliteration of the distal pulmonary arteries. Persistent increases in pulmonary vascular resistance lead to right heart failure and ultimately death. While current therapeutics reduce pulmonary arterial pressure, and increase time to death or transplant, median survival is remains only five to seven years from the time of diagnosis. Unlike selective pulmonary vasodilators alone, approaches directed at inflammatory vascular remodeling have the potential to arrest or even reverse the disease.

Dr. Elinoff's research focus is the contributions of pulmonary vascular endothelium and immune effector cells to the development and progression of PAH. Current work includes in vitro profiling of human pulmonary artery endothelial cells with heterogeneous PAH-associated molecular defects in order to investigate molecular mechanisms that can exploited therapeutically. The overarching goal of the program is to translate basic science and pre-clinical studies to early phase therapeutic trials in PAH patients.

Dr. Elinoff earned his undergraduate degree in Chemistry from Princeton University and his degree in Medicine from the University of Chicago Pritzker School of Medicine. He went on to complete internship and residency training in Internal Medicine at the Massachusetts General Hospital.

Dr. Elinoff completed fellowship training in Critical Care Medicine at the NIH Clinical Center and Pulmonary and Critical Care Medicine at Johns Hopkins University.

See his Intramural Research Program bio page.

  • Bench to Bedside Award: Repurposing Empagliflozin for the Treatment of G6PC3 Deficiency, 2020
  • NIH Clinical Center CEO Award, 2020
  • NIH Bench-to-Bedside Award, "Role of AR and ER Signaling in Pulmonary Arterial Hypertension", 2011
  • NIH Clinical Center Director's Award, 2010
  • Alpha Omega Alpha, University of Chicago Pritzker School of Medicine, 2004
  • HHMI Continued Fellowship for Medical Studies 2003-2004
  • HHMI-NIH Research Scholar 2002
  • Everett S. Wallis Prize in Organic Chemistry, Princeton University, 1999
  • Magna Cum Laude, Department of Chemistry, Princeton University, 1999

Lu M, Chen LY, Gairhe S, Mazer AJ, Anderson SA, Nelson JNH, Noguchi A, Siddique MAH, Dougherty EJ, Zou Y, Johnston KA, Yu ZX, Wang H, Wang S, Sun J, Solomon SB, Vanderpool RR, Solomon MA, Danner RL, Elinoff JM. Mineralocorticoid Receptor Antagonist Treatment of Established Pulmonary Arterial Hypertension Improves Interventricular Dependence in SU5416-Hypoxia Rat Model. Am J Physiol Lung Cell Mol Physiol. 2022 Jan 19. doi: 10.1152/ajplung.00238.2021. Online ahead of print.PMID: 35043674

Gairhe S, Awad KS, Dougherty EJ, Ferreyra GA, Wang S, Yu ZX, Takeda K, Demirkale CY, Torabi-Parizi P, Austin ED, Elinoff JM, Danner RL. Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension. Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):e2010206118. doi: 10.1073/pnas.2010206118.PMID: 33836561

Brusca SB, Zou Y, Elinoff JM. How low should we go? Potential benefits and ramifications of the pulmonary hypertension hemodynamic definitions proposed by the 6th World Symposium. Curr Opin Pulm Med. 2020 Sep;26(5):384-390. doi: 10.1097/MCP.0000000000000699.PMID: 32701671

Rhodes CJ, Otero-Núñez P, Wharton J, Swietlik EM, Kariotis S, Harbaum L, Dunning MJ, Elinoff JM, Errington N, Thompson AAR, Iremonger J, Coghlan JG, Corris PA, Howard LS, Kiely DG, Church C, Pepke-Zaba J, Toshner M, Wort SJ, Desai AA, Humbert M, Nichols WC, Southgate L, Trégouët DA, Trembath RC, Prokopenko I, Gräf S, Morrell NW, Wang D, Lawrie A, Wilkins MR. Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. Am J Respir Crit Care Med. 2020 Aug 15;202(4):586-594. doi: 10.1164/rccm.202003-0510OC.PMID: 32352834

Elinoff JM, Mazer AJ, Cai R, Lu M, Graninger G, Harper B, Ferreyra GA, Sun J, Solomon MA, Danner RL.Meta-analysis of blood genome-wide expression profiling studies in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2020 Jan 1;318(1):L98-L111. doi: 10.1152/ajplung.00252.2019. Epub 2019 Oct 16.

Elinoff JM, Agarwal R, Barnett CF, Benza RL, Cuttica MJ, Gharib AM, Gray MP, Hassoun PM, Hemnes AR, Humbert M, Kolb TM, Lahm T, Leopold JA, Mathai SC, McLaughlin VV, Preston IR, Rosenzweig EB, Shlobin OA, Steen VD, Zamanian RT, Solomon MA.Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. Am J Respir Crit Care Med. 2018 Jul 15;198(2):166-174. doi: 10.1164/rccm.201710-2093PP.PMID: 29425462

Elinoff JM, Chen LY, Dougherty EJ, Awad KS, Wang S, Biancotto A, Siddiqui AH, Weir NA, Cai R, Sun J, Preston IR, Solomon MA, Danner RL Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling. Cardiovasc Res. 2018 Jan 1;114(1):65-76. doi: 10.1093/cvr/cvx198.PMID: 29036418 Free PMC article.

Visit PubMed.gov for a full list of Dr. Elinoff's publications.